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Cellular senescence is a stable state of prolifer-
ative arrest that provides a barrier to malignant
transformation and contributes to the antitumor
activity of certain chemotherapies. Senescent
cells can accumulate senescence-associated
heterochromatic foci (SAHFs), which may pro-
vide a chromatin buffer that prevents activation
of proliferation-associated genes by mitogenic
transcription factors. Surprisingly, we show
that the High-Mobility Group A (HMGA) pro-
teins, which can promote tumorigenesis, accu-
mulate on the chromatin of senescent fibro-
blasts and are essential structural components
of SAHFs. HMGA proteins cooperate with the
p16INK4a tumor suppressor to promote SAHF
formation and proliferative arrest and stabilize
senescence by contributing to the repression
of proliferation-associated genes. These anti-
proliferative activities are canceled by coex-
pression of the HDM2 and CDK4 oncogenes,
which are often coamplified with HMGA2 in hu-
man cancers. Our results identify a component
of the senescence machinery that contributes
to heterochromatin formation and imply that
HMGA proteins also act in tumor suppressor
networks.
INTRODUCTION
Cellular senescence was originally defined as the state
of proliferative arrest that accompanies the replicative
exhaustion of cultured human cells (Hayflick, 1965).
Whereas ‘‘replicative’’ senescence is triggered by telo-
mere erosion, an indistinguishable phenotype can be in-
duced in ‘‘young’’ cells by activated oncogenes, chemo-
therapeutic drugs, oxidative stress, and suboptimal
culture conditions (Campisi, 2005). Once considered anin vitro phenomenon, recent studies underscore the role
of senescence in limiting oncogene-initiated tumorigene-
sis and enhancing the antitumor effects of some cancer
drugs (Braig et al., 2005; Chen et al., 2005; Collado
et al., 2005; Lazzerini Denchi et al., 2005; Michaloglou
et al., 2005; Roninson, 2003; Schmitt et al., 2002). Some
genes linked to senescence in vitro also influence organ-
ismal life span in vivo, raising the possibility that the senes-
cence program affects the balance between cancer and
aging (Campisi, 2005).
The senescence program is best understood in normal
diploid human fibroblasts, where cells undergo a series of
events leading to marked morphological changes, the ex-
pression of a senescence-associated (SA) b-galactosi-
dase, and diverse changes in gene expression, including
upregulation of the INK4a cyclin-dependent kinase inhib-
itor (Dimri et al., 1994; Shelton et al., 1999). Most impor-
tantly, senescent cells remain permanently insensitive to
mitogenic signals, owing to the combined action of the
p53 and p16INK4a-Rb tumor suppressor networks, which
are frequently disabled in cancer cells (Ben-Porath and
Weinberg, 2004). Thus, much like apoptosis, cellular se-
nescence appears to involve an intricate program that
actively suppresses tumorigenesis.
Although the stability of senescence presumably con-
tributes to its antineoplastic activities, the molecular ma-
chinery that drives the cell into a permanent state of pro-
liferative arrest is poorly understood. In some cell types,
senescence is associated with global changes in chroma-
tin structure, leading to the accumulation of heterochro-
matin protein 1 (HP1) and histone H3 trimethylated on
lysine 9 (me-K9H3) in senescence-associated heterochro-
matic foci (SAHFs) and on the promoters of certain cell-
cycle genes (Narita et al., 2003; Zhang et al., 2005). Im-
portantly, changes in heterochromatin organization are
observed in apparently senescent cells present in prema-
lignant tumors (Braig et al., 2005; Chan et al., 2005; Col-
lado et al., 2005; Lazzerini Denchi et al., 2005), and mole-
cules that are required for these changes can contribute to
senescence in vitro and in vivo (Braig et al., 2005; Narita
et al., 2003). Such changes could promote senescence
by producing a repressive chromatin environment thatCell 126, 503–514, August 11, 2006 ª2006 Elsevier Inc. 503
prevents transcription of growth-promoting genes,
thereby producing an extreme insensitivity to mitogenic
stimulation.
The HMGA1 (formerly HMGI-Y) and HMGA2 (formerly
HMGI-C) proteins are abundant nonhistone chromatin
proteins encoded by two distinct genes and have three
AT-hook domains that bind the minor groove of AT-rich
DNA sequences (Reeves, 2001; Sgarra et al., 2004). In
contrast to HP1, HMGA proteins are typically associated
with gene activation and have been linked to proliferation
(Reeves et al., 2001). Thus, both HMGA genes are highly
expressed in the embryo and downregulated during differ-
entiation (Zhou et al., 1995) and both are induced by mito-
genic stimuli (Lanahan et al., 1992). In fact, HMGAproteins
can promote tumorigenesis (Takaha et al., 2004) and are
often overexpressed in tumors, particularly those of mes-
enchymal origin (Reeves, 2001). HMGA transgenic mice
develop tumors after a long latency (Fedele et al., 2002,
2005), and gene amplifications and translocations of
HMGA genes occur in human cancers (Reeves, 2001;
Sgarra et al., 2004).
Here we take a biochemical approach to characterize
the chromatin composition of senescent cells. Surpris-
ingly, we identify HMGA1 and HMGA2 as proteins that
specifically accumulate on senescent cell chromatin,
and we show that they act as structural components of
SAHFs and contribute to the stable repression of prolifer-
ation-associated genes. Consequently, HMGA proteins
act with other senescence regulators to stabilize the sen-
escent state. These studies identify a new activity for
HMGA proteins and suggest that they can have both on-
cogenic and antioncogenic properties.
RESULTS
Senescent Cells Have a Distinct Pattern
of Chromatin-Associated Proteins
To further characterize chromatin changes that contribute
to cellular senescence, we examined the protein composi-
tion of chromatin preparations from quiescent (reversibly
arrested) and senescent normal diploid IMR90 fibroblasts.
Senescent IMR90 populations were produced following
retroviral delivery of oncogenic ras, which synchronously
induces senescence in vitro and may recapitulate relevant
senescence-inducing signals in vivo (Braig et al., 2005;
Collado et al., 2005). Nuclei were isolated at various times
and subjected to a no-salt extraction procedure that en-
riches for chromatin-associated proteins (Mendez and
Stillman, 2000). As expected, ras-senescent cells dis-
played SAHFs that were enriched for HP1g and excluded
histone H3 acetylated on Lys9/14 (Ac-K9/14H3), a euchro-
matic marker (Figure 1A). Furthermore, these morphologi-
cal changes were accompanied by a corresponding in-
crease in HP1g bound to chromatin and a decrease in
Ac-K9/14H3 (Figure 1B). In contrast, quiescent cells dis-
played a nuclear morphology and pattern of chromatin-
associated proteins that, at this level of resolution, were504 Cell 126, 503–514, August 11, 2006 ª2006 Elsevier Inc.indistinguishable from growing cells (Figure 1B; data not
shown).
Using Coomassie staining to visualize the protein com-
position of each chromatin preparation, we also noticed
that several unknown proteins were either enriched or de-
pleted from chromatin preparations in senescent cells.
Among these were two low-molecular-weight polypep-
tides, designated bands 1 and 2, that accumulated on
senescent cell chromatin, with band 1 appearing early
and band 2 coinciding with the appearance of SAHFs.
This pattern was not unique to IMR90 cells since senes-
cent WI38 cells also displayed prominent SAHFs and ac-
cumulated proteins corresponding to both both band 1
and band 2 (Figure 1C). However, senescent BJ fibro-
blasts, which poorly express p16INK4a and are less stably
arrested (Beausejour et al., 2003), displayed fewer SAHFs
and only accumulated band 1 on chromatin (Figure 1C).
These data confirm that gross changes in chromatin
composition accompany senescence.
The High-Mobility Group A Proteins Accumulate
on Chromatin during Senescence
The experiments described above identify new proteins
that might influence chromatin structure during senes-
cence. We therefore subjected bands 1 and 2 to micro-
sequencing by mass spectrometry. Multiple peptides cor-
responding to HMGA1 (band 1) and HMGA2 (band 2) were
recovered from two independent chromatin preparations
(Figure 1D), and immunoblotting using HMGA1- or
HMGA2-specific antibodies confirmed that each protein
was enriched on senescent cell chromatin (Figure 1E,
compare lane 3 to lanes 1 and 2). Furthermore, bands 1
and 2 were selectively depleted from chromatin prepara-
tions isolated from cells coexpressing ras and short-hair-
pin RNAs (shRNAs) capable of suppressing HMGA1 and
HMGA2, respectively (Figure 1F). Thus, both HMGA1
and HMGA2 specifically accumulate on chromatin in
senescent IMR90 cells.
These results were unexpected as HMGA proteins
levels often increase in tumor cells (Reeves, 2001). To ex-
amine the relationship between HMGA expression and
proliferation in our system, we measured the total levels
of HMGA1 and HMGA2 in growing, quiescent, and senes-
cent IMR90 cells. Relative to growing cells, HMGAmRNA
and protein levels were increased in cells triggered to un-
dergo senescence by oncogenic ras, etoposide, or repli-
cative exhaustion, but not during quiescence produced
by confluence or serum starvation (Figures 1G and S1;
data not shown). Consistent with previous reports (Lana-
han et al., 1992), serum-starved cells showed a reduction
in HMGA expression, although confluent cells did not
(Figure 1G, compare lane 1 to lanes 2 and 3). Adenovirus
E1A, which prevents SAHF formation, cyclin A downregu-
lation, and senescence, abolished the increase in HMGA
protein levels and in fact repressed HMGA2 (Figure 1G,
compare lane 4 to 5). Hence, HMGA can be induced by
either mitogenic or prosenescence signals.
Figure 1. HMGA Proteins Accumulate on
Chromatin during Cellular Senescence
(A) Merged confocal images for indirect immu-
nofluorescence of HP1g (green) and Ac-K9/
14H3 (red) in normal growing (Growing) and
ras-induced senescent (Senescent) IMR90
cells.
(B) Chromatin protein profile in quiescent (Q),
normal growing (G), and ras-induced senes-
cent IMR90 (Ras) cells at different times after
selection for ras-expressing cells. SDS-PAGE
was followed by immunoblotting for HP1g
and Ac-K9/14H3 and Coomassie blue staining.
Arrows show bands 1 and 2; unlabeled arrow
shows histone H3.
(C) Chromatin fractions from quiescent (Q) and
ras-induced senescent (Ras) IMR90, WI38, and
BJ cells were resolved in SDS-PAGE followed
by Coomassie blue staining. Arrows show
bands 1 and 2.
(D) Recovered peptide sequences (red) from
those two bands (B, arrows) by mass-spec-
trometry analysis correspond to HMGA1 and
HMGA2.
(E) Western blotting for HMGA proteins in chro-
matin fractions from the indicated cells. Coo-
massie staining visualizes core histones and
serves as a loading control. E/R; E1A/ras-
transformed cells.
(F) Chromatin fractions from IMR90 cells ex-
pressing both ras and either a control vector
(V) or an shRNA for HMGA (sh-A1 or sh-A2)
were resolved in SDS-PAGE followed by Coo-
massie blue staining or immunoblotting for
HMGA and HP1g.
(G) Immunoblotting of the indicated cell lysates
for HMGA proteins and cyclin A, with actin or
tubulin serving as a loading control. Shown
are the following: G, growing; C, confluent;
LS, low serum; R, ras; E/R, E1A/ras-trans-
formed; Etoposide+, DNA damage-induced
senescent cells.HMGA Proteins Colocalize with SAHFs
We next examined the subcellular localization of each
HMGA protein using indirect immunofluorescence. In
growing and quiescent cells, HMGA1 and HMGA2 were
expressed diffusely throughout the nucleus except for
pronounced foci that corresponded to the inactive X chro-
mosome (Figure S2; see also Chadwick and Willard, 2003
and Harrer et al., 2004), a well-characterized heterochro-
matic structure that is prominent in IMR90 cells (Heard
et al., 2001). In contrast, in senescent cells, HMGA1 and
HMGA2 were predominantly localized to DAPI-dense
SAHFs that also contained the heterochromatin protein
HP1g (Figure 2A; data not shown) and excluded the eu-
chromatic markers Ac-K9/14H3 and K4 trimethyl histone
H3 (me-K4H3) (Figure S3). Electronmicroscopy confirmed
these results, where the immunogold staining for both
HMGA proteins colocalized with the electron-dense re-
gions that correspond to SAHFs (Narita et al., 2003)
(Figure 2B). These results were surprising, asmost studieslink HMGA proteins with open chromatin configurations
(Reeves, 2001).
HMGA proteins enhance transcription, in part through
their ability to associate with the minor groove of AT-rich
DNA sequences (Reeves, 2001). To determine whether
the association of HMGAwith SAHFs requires this activity,
we treated SAHF-positive cells with Hoechst 33258,
a membrane-permeable DNA dye that binds the minor
groove of AT-rich DNA and displaces HMGA proteins
from chromatin (Radic et al., 1992). Senescent IMR90
cells were treated with Hoechst 33258 for 2 days and
then subjected to subcellular fractionation to assess the
specificity of competition or examined for SAHFs.
Whereas Hoechst 33258 had no impact on the distribution
of the HP1 proteins, it was able to displace both HMGA1
and HMGA2 from the chromatin fraction (Figure 2C, com-
pare lanes 3 and 6). Hoechst-treated cultures also dis-
played fewer SAHF-positive cells (Figures 2D and 2E),
suggesting that HMGA proteins are integral SAHFCell 126, 503–514, August 11, 2006 ª2006 Elsevier Inc. 505
Figure 2. HMGA Proteins Are Enriched in SAHFs
(A) Representative confocal images of indirect immunofluorescence of HMGA1 or HMGA2, and HP1g.
(B) Electron microscope images of senescent cells following immunogold labeling of HMGA1 or HMGA2. Lower panels; higher magnification of
HMGA-containing SAHF.
(C–E) Hoechst competition assay. The amount of indicated proteins was determined by immunoblotting of indicated fractions in the presence (lanes
4–6) or absence (lanes 1–3) of Hoechst 33258 (Hoe) (C). The cells were assessed for SAHF formation (D). Representative images of the nuclei stained
with DAPI are shown with the control nuclei of normal growing cells (E). Shown are the following: CP, cytoplasmic; NP, nucleoplasmic; Ch, chromatin
fraction. Values represent the mean ± standard error of three experiments.components (see below). Identical results were obtained
using distamycin A, which also binds the minor groove
of AT-rich DNA (data not shown) (Radic et al., 1992).
Thus, HMGA proteins apparently associate with these
heterochromatic structures via their canonical biochemi-
cal activity.
HMGA Proteins Promote SAHF Formation
and Senescence
To determine whether HMGA proteins are sufficient to in-
duce SAHFs or other senescence phenotypes, we ectop-
ically expressed each HMGA gene in IMR90 cell popula-
tions. We used retroviruses that expressed HMGA
tagged with hemagglutinin (HA) or fused to green fluores-
cent protein (GFP) from either the strong CMV promoter or
the weaker LTR promoter, leading to different levels of
transgene expression (Figure 3A). Cells expressing high
levels of either HMGA protein underwent an acute cell cy-
cle arrest and displayed features of senescence, including
increases in p16INK4a and p53, a senescent morphology,
and elevated SA-b-galactosidase activity (Figures 3A
and 3B). These cells also acquired SAHF-like foci that
contained HMGA and me-K9H3 (Figure 3C; data not
shown).
Cells expressing HMGA1 from the weaker LTR pro-
moter, contained near endogenous levels (Figure 3A),
did not acutely arrest but grew similarly to controls—at
least initially (Figure 3D). However, these cells underwent
replicative exhaustion earlier (Figure 3D), showing a506 Cell 126, 503–514, August 11, 2006 ª2006 Elsevier Inc.more rapid onset of senescent morphology and p16INK4a
and p53 induction and SAHF formation (data not shown).
Similar results were obtained for cells expressing physio-
logic levels of HMGA2 (Figure S4). Therefore, HMGA pro-
teins are able to induce SAHFs and other senescence
phenotypes when overexpressed and cooperate with
other factors to accelerate senescence at physiologically
relevant levels.
p16INK4a and HMGA Induce SAHFs in a Mutually
Reinforcing Manner
Although HMGA proteins can induce p16INK4a when over-
expressed, enforced expression of p16INK4a is sufficient to
induce SAHFs (Narita et al., 2003), which contain HMGA
(see above). We therefore performed epistasis tests to
study the relationship between HMGA and p16INK4a in
the senescence program. We first coexpressed HMGA1
(using the strong CMV promoter) with an INK4a-specific
shRNA (sh-p16) or a control vector in IMR90 cells and
measured DNA synthesis and SAHF formation using
BrdU incorporation and DAPI staining, respectively.
HMGA1-induced arrest and SAHF formation were clearly
impaired in cells expressing sh-p16, despite having similar
levels of transgene expression (Figure 3E). We also tested
the effect of p53 inactivation using a p53 shRNA (sh-p53)
or dominant-negative mutant p53175H (DN) and found that
p53 had less impact on HMGA-induced senescence
(Figure 3E). Of note, cells expressing either shRNA alone
or together reached replicative senescence earlier than
Figure 3. HMGA Proteins Promote SAHF Formation and Senescence
(A) IMR90 cells expressing the GFP-fusion HMGA proteins driven by LTR (pWZL) or CMV (pLPC) promoter were lysed and subjected to immunoblot-
ting using antibodies against HMGA1, HMGA2, p16INK4a, or p53. The percentage of the BrdU-positive cells is shown below each lane.
(B) IMR90 cells expressing GFP or GFP-HMGA1 from CMV promoter were assessed for SA-b-galactosidase activity.
(C) Fluorescent images of IMR90 cells expressing GFP or GFP-HMGA fusion proteins (GFP-A1 or GFP-A2) from the CMV promoter. IMR90 cells ex-
pressing GFP-HMGA1 were also immunolabeled for me-K9H3. Nuclei were counterstained with DAPI.
(D) Growth curves of IMR90 cells expressing a control GFP, GFP-HMGA1 from the retroviral LTR, or GFP-HMGA1 from CMV promoter.
(E) IMR90 cells expressing a control vector (V) or GFP-tagged HMGA1 (GFP-A1) from the CMV promoter together with a vector (V), an shRNA against
INK4a (sh-p16) or p53 (sh-p53), or dominant-negative mutant p53175H (p53DN) were assessed for BrdU incorporation and SAHF formation. The inset
shows the expression levels of GFP-HMGA1 (GFP-A1), p16INK4a, and p53with actin as a loading control. Values are themean ± standard error of three
experiments.
(F and G) IMR90 cells expressing vector alone (V), or V, shRNA against HMGA1 (sh-A1) together with p16INK4a were analyzed for expression of the
indicated proteins by immunoblotting (F) and SAHF formation with DAPI staining (G) 7 days after retroviral transduction. Values are the mean ± stan-
dard error of three experiments.controls, indicating that disruption of p16INK4a and/or p53
is not sufficient to completely bypass HMGA-induced
arrest (data not shown).
We next coexpressed p16INK4a in the presence or ab-
sence of an HMGA1 shRNA. p16INK4a also efficiently in-
duced both HMGA proteins, which localized to SAHFs(Figure 3F; data not shown). Furthermore, the HMGA1
shRNA completely prevented SAHF accumulation in re-
sponse to p16INK4a (Figures 3F and 3G), although these
cells eventually arrested. Thus, HMGA and p16INK4a
act in a mutually reinforcing manner to promote SAHF
formation.Cell 126, 503–514, August 11, 2006 ª2006 Elsevier Inc. 507
Figure 4. HMGA Proteins Are Required
for SAHF Formation and Cooperate with
p16 to Promote Senescence
(A) IMR90 cells expressing vector alone (V), or
a combination of H-ras V12 (Ras) and vector
(V), shRNA against HMGA1 (sh-A1), HMGA2
(sh-A2), INK4a (sh-p16), or p53 (sh-p53), or
dominant-negative mutant p53175H (p53-DN)
were analyzed for expression of the indicated
proteins 7 days after retroviral transduction.
Note that cells with sh-p16, sh-p53, or p53-
DN still induce HMGA proteins that are chro-
matin bound (Figures 5A and S8), indicating
that HMGA is not directly responding to
p16INK4a or p53.
(B) The cell populations described in (A) were
assessed for BrdU incorporation and SAHF for-
mation, with values representing the mean ±
standard error of at least three experiments.
(**) denotes significance values of p < 0.01 rel-
ative to V/Ras cells.
(C) IMR90 cells expressing vector alone (V), or
a combination of H-rasV12 (Ras) and vector
(V), shRNA against HMGA1 (sh-A1), HMGA2
(sh-A2), or INK4a (sh-p16) were plated
1 3 104/3.5 cm at 9 days after retrovirus infec-
tion and assessed for the expression of the
indicated proteins 32 days after infection. Cells
were maintained in selective media to ensure
retention of the ras-expressing retrovirus.
(D) IMR90 cells coexpressing ras andGFP [Ras
(GFP)] with indicated combination of shRNAs
(sh) against HMGA1 (A1), INK4a (p16), and
p53 (p53) were assessed for BrdU incorpora-
tion and SAHF formation in the GFP-positive
population 7 days after lentiviral infection, as
in Figure 4B. Values are the mean ± standard
error of three experiments. (*) or (**) denotes
significance values of p < 0.05 or p < 0.01, re-
spectively, relative to V/Ras cells.
(E and F) The indicated cell populations were
plated in three different densities 10 days after
retroviral gene transduction and assessed for
the colony formation with Crystal violet staining
20 days later. (E). Cells weremaintained in se-
lective media (Blasticidin) to ensure retention of
the ras-expressing retrovirus. The intensity of
Crystal violet of 3 3 103/3.5 cm series was
measured with ImageJ software, with values
representing the mean ± standard error (n = 5) (F). (*) represents significance values of p = 0.01 relative to V/V/Ras cells. The mean value of two in-
dependent experiments for each sh-p53/Ras or p53 dominant-negativemutantp53175H (DN)/Ras population is also shownwith a representative value
of sh-p16/sh-p53/Ras population as a positive control.HMGA Proteins Are Required for SAHF Formation
and Complete Proliferative Arrest during
Senescence
We also examined the contribution of each HMGA protein
to various senescence phenotypes. Acute knockdown of
each HMGA protein alone had no obvious effect on prolif-
eration (data not shown). However, 7 days after transduc-
tion with oncogenic ras, cells expressing sh-HMGA1 (sh-
A1) or sh-HMGA2 (sh-A2) (Figure 4A) showed reduced
SA-b-galactosidase activity (Figure S5), increased BrdU
incorporation, and decreased SAHF formation compared508 Cell 126, 503–514, August 11, 2006 ª2006 Elsevier Inc.to controls (Figure 4B; see also Figure S6 for results using
additional HMGA shRNAs). In fact, cells expressing sh-A1
were almost completely devoid of SAHFs (Figure 4B),
even though they expressed high levels of endogenous
p16INK4a (Figure 4A, compare lanes 2–4).
Both HMGA shRNAs enabled some cells to bypass se-
nescence, leading to a modest increase in colony forma-
tion that was similar to that produced by an INK4a shRNA
(Figure 4E; data not shown). HMGA1 and HMGA2 have
similar structures and share some transcriptional targets
(Baldassarre et al., 2001), suggesting that these proteins
Figure 5. HMGA Proteins Are Essential
Components of SAHF and Required for
the Stable Suppression of Proliferation-
Associated Genes
(A–C) Lentivirus-expressing miR30 control (V),
shRNA (sh) against HMGA1 (A1), HMGA2
(A2), or INK4a (p16), or dominant-negative
p53 peptide (GSE22) was introduced into ras-
senescent IMR90 cells. Five days later, cells
were analyzed for expression of the indicated
proteins by immunoblotting (A) and for SAHF
formation with DAPI staining (B and C). Values
represent the mean ± standard error of at least
three experiments. (**) denotes significance
values of p < 0.01 relative to vector (V)-contain-
ing cells.
(D) mRNA levels of indicated genes and DNA
synthesis were determined by quantitative
RT-PCR and BrdU incorporation 5 days after
retroviral transduction of the indicated gene.
Values represent the mean ± standard error of
three independent experiments.might have overlapping functions in senescence (see also
Tables S1–S4). Accordingly, cosuppression of HMGA1
and HMGA2 did not enhance the phenotype produced
by sh-A1 alone (data not shown), although we cannot
rule out the possibility that more effective shRNAs would
cooperate. Thus, HMGA proteins contribute to senes-
cence but necessarily must act in concert with additional
factors to do so.
HMGA shRNA-expressing cells that formed colonies, at
32 days after infection, retained ras expression but had
much lower p16INK4a levels than senescent cells
(Figure 4C, compare lane 2 to lanes 3 and 4), suggesting
that reduced p16INK4a activity was also required for senes-
cence bypass. We therefore examined the impact of co-
suppressing HMGA1 and p16INK4a on proliferation follow-
ing a senescence trigger (i.e., oncogenic ras). In acute
proliferation assays, cells coexpressing both HMGA1
and INK4a shRNAs showed a DNA synthesis rate that
was substantially greater than cells expressing either
shRNA alone and comparable to growing cells or cells co-
expressing p53 and INK4a shRNAs (Figure 4D). In con-
trast, cosuppression of HMGA1 and p53 did not show
a synergistic effect on proliferation (Figure 4D). In long-
term assays, cells expressing both HMGA1 and INK4a
shRNAs with ras formed colonies efficiently at numbersthat approached those produced by cells coexpressing
p53 and INK4a shRNAs (Figures 4E and 4F). Therefore,
consistent with their action in a nonlinear pathway,
HMGA and p16INK4a cooperate to promote SAHF forma-
tion and senescence.
HMGA Proteins Are Essential Components of SAHFs
and Are Required for the Stable Suppression of
Proliferation-Associated Genes
The Hoechst competition experiments described above
suggest that HMGA proteins are essential for maintaining
SAHF integrity. To examine this more directly, senescent
IMR90 cell populations were transduced with lentiviral
vectors expressing the shRNAs targeting HMGA1,
HMGA2, or INK4a, as well as dominant-negative p53 pep-
tide (GSE22) (Beausejour et al., 2003). These vectors effi-
ciently transduced senescent cells and suppressed their
corresponding targets (Figures 5A and 5D; data not
shown). SAHF morphology was unaffected by p16INK4a
depletion, indicating that p16INK4a is required for SAHF es-
tablishment but not maintenance. SAHF morphology was
also unaffected by p53 inactivation (Figures 5B and 5C). In
contrast, SAHFs could be dissolved by suppression of ei-
ther HMGA protein, with loss of HMGA1 producing an al-
most complete effect (Figures 5B and 5C). Consistent withCell 126, 503–514, August 11, 2006 ª2006 Elsevier Inc. 509
the Hoechst experiments (Figure 2C), HP1g remained
chromatin bound (Figure S7). Thus, HMGA proteins are
essential components of these heterochromatic struc-
tures and promote senescence in parallel to HP1.
p16INK4a contributes to senescence, in part by trigger-
ing stable repression of E2F target genes (Narita et al.,
2003). Since SAHFs have been associated with this activ-
ity (Narita et al., 2003), we assessed the impact of sup-
pressing p16INK4a—alone or in combination with sup-
pressing HMGA1—on the expression of selected E2F
target genes (Figure 5D). Senescent (SAHF-positive)
IMR90 cells were transduced with lentiviral vectors ex-
pressing shRNAs targeting HMGA1 and/or INK4a, and
the resulting cell populations were examined for their abil-
ity tomaintain E2F target gene suppression and to synthe-
size DNA 5 days later. Cosuppression of both HMGA and
INK4a increased the expression of cyclin A and Mcm3
more efficiently than either shRNA alone (Figure 5D). In
contrast, none of the shRNAs tested increased PCNA ex-
pression at this time point, implying that proteins in addi-
tion to HMGA1 and p16INK4a can contribute to gene silenc-
ing or that PCNA is more responsive to residual HMGA
and/or p16INK4a protein levels. A substantial percentage
of cells cosuppressing p16INK4a and HMGA1 re-entered
S phase, an effect that did not occur in cells suppressing
either p16 INK4a or HMGA1 alone (Figure 5D). Therefore,
HMGA proteins cooperate with p16INK4a to stably repress
E2F target genes in senescent cells.
HMGA Proteins Regulate Gene Expression
Depending on Cellular Contexts
We also conducted a series of microarray experiments to
identify genes affected by HMGA1 and HMGA2 in normal
and senescent cells. IMR90 cells were transduced with
shRNAs targeting either HMGA1 or HMGA2, simulta-
neously transduced with a control vector, or triggered to
undergo senescence by oncogenic ras, and differentially
expressed genes were identified using Affymetrix U133
Plus 2.0 expression arrays. Interestingly, the vast majority
of genes that were differentially expressed (R2-fold) in
senescent cells expressing HMGA shRNAs were upregu-
lated, indicating aprominent role forHMGA ingene repres-
sion (Figure 6A). This is in contrast to normal IMR90 cells,
where there were similar numbers of up- and downregu-
lated genes (Figure 6A), or ES cells, where HMGA1 mainly
increases gene expression (Martinez Hoyos et al., 2004).
Although there was some overlap, most of the genes
controlled by HMGA proteins in senescent cells were dis-
tinct from those affected by HMGA in normal cells
(Figure 6B). Thus, whereas pathway annotation analysis
of the HMGA-controlled genes identified genes linked to
‘‘cytokine-cytokine receptor interaction,’’ as overrepre-
sented in datasets from both normal (p = 0.00032 for
HMGA1; p = 0.00033 for HMGA2) and senescent cells
(Tables S1–S4, p = 0.00031 for HMGA1; p = 0.0010 for
HMGA2), genes linked to the ‘‘cell cycle’’ were overrepre-
sented only in datasets derived from cells triggered to sen-
esce (p = 0.026 for HMGA1; p = 1.9E-10 for HMGA2).510 Cell 126, 503–514, August 11, 2006 ª2006 Elsevier Inc.Among the genes repressed by both HMGA proteins only
in senescent cells were E2F targets, including CDC2,
MCMs, andcyclinA. However, neither INK4anor canonical
p53-responsive geneswere affectedbyHMGA in this anal-
ysis. Our data therefore associate HMGA with the repres-
sion of cell-cycle genes in senescent cells.
Oncogenic Lesions Bypass HMGA-Induced
Senescence
Although both HMGA1 and HMGA2 can act as onco-
genes, our results imply that each also contributes to cel-
lular senescence, an antioncogenic program. Accordingly,
we see that loss of p16INK4a and p53 attenuates the acute
induction of senescence by HMGA proteins (Figure 3E;
data not shown), suggesting that high HMGA levels may
only be oncogenic if the senescence program is disabled.
Interestingly,HMGA2 is located near theHDM2 andCDK4
loci on chromosome 12q13-15 and is often coamplified
with bothHDM2 andCDK4 (Berner et al., 1997), which tar-
get the p53 and p16-Rb pathways, respectively. To di-
rectly determine whether these lesions bypass HMGA-
induced senescence, we overexpressed HMGA2 with
HDM2 and/or CDK4 in IMR90 cells and assessed their
long-term proliferative potential. Here, cells were selected
with three consecutive drug treatments to obtain the pure
populations coexpressing three genes, a procedure which
ultimately shortened their general replicative life span
(Figure 7B). Still, cells coexpressing HDM2 and CDK4 by-
passed HMGA2-induced arrest and SAHF formation (data
not shown), displaying a dramatically extended life span
even despite high levels of HMGA2 (Figures 7A and 7B).
Figure 6. Regulation of GeneExpression byHMGAProteins Is
Context Dependent
Gene expression profiles of vector (V) or ras-expressing IMR90 cells
transduced with an sh-RNA against HMGA1 or HMGA2 were com-
pared to cells transduced with a control vector.
(A) Shown are the percentages of upregulated genes out of all the
genes differentially expressed (R 2-fold) in response to sh-HMGA1
(left) or sh-HMGA2 (right). Similar results were obtained using more
stringent cutoffs (3-fold or 4-fold difference) or various normalization
methods (data not shown).
(B and C) Venn diagram showing the numbers of genes upregulated by
sh-HMGA1 (B) or sh-HMGA2 (C) in growing (V) and ras-senescent
(Ras) cells. The overlaps illustrate genes commonly upregulated in
both cellular contexts.
Figure 7. The Action of HMGA Proteins in Senescence Depends on Intact Senescence Machinery
(A) IMR90 cells expressing GFP-HMGA1 (A1), HA-HMGA2 (A2), HDM2 (H), CDK4 (C), or corresponding control vectors (V) in the indicated combina-
tions were assessed for the indicated ectopic proteins with actin as a loading control.
(B) Population-doubling analysis of the cells described in (A). Cell number was plotted after completion of three consecutive selections for the trans-
duced marker genes. The inset shows the expression of ectopic HMGA proteins over time.
(C) A representative focus formation assay using IMR90 cells expressing E1A (E), ras (R), and pLPC vector (L) or HA-tagged HMGA2/pLPC (A2).
(D) Tumorigenicity assay using two independent preparations of the cells described in (C) injected subcutaneously into immunocompromised mice.
(E) Two representative images of mice in (D) injected with E1A/ras cells (left flank) or E1A/ras/HMGA2 (right flank) containing cells.Cells expressing either HDM2 or CDK4 alone had an inter-
mediate phenotype (Figure 7B). Similar results were ob-
tained with HMGA1 (Figure 7B). Therefore, the same le-
sions linked to HMGA amplification in human cancers
circumvent its antiproliferative activity.
To determine whether disruption of senescence might
expose the oncogenic potential of HMGA proteins, we in-
troduced HA-tagged HMGA2 into IMR90 cells coexpress-
ing E1A (which inactivates Rb and prevents p53-mediated
arrest) and oncogenic ras. These cells otherwise express
extremely low levels of HMGA2 (Figure 1G, lane 5), fail to
senesce, and are weakly transformed (Seger et al.,
2002). As expected, control cells expressing E1A and
ras formed some multilayered foci and were weakly tu-
morigenic following transplantation into immunocompro-
mised mice (Figures 7C–7E). However, HMGA2 expres-sion clearly enhanced these effects, leading to more
transformed foci, increased tumor penetrance, and de-
creased tumor latency relative to controls. Of note, the
level of HMGA2 protein that enhanced transformation of
cells expressing E1A/ras was more than senescent cells
expressing ras alone (Figure 7D, inset). Thus, HMGA2
can have antioncogenic or oncogenic properties in
IMR90 cells depending on the integrity of the senescence
machinery.
DISCUSSION
Our observations expand our understanding of HMGA bi-
ology, as well as their role in chromatin organization and
cancer. We see that HMGA proteins accumulate on chro-
matin in senescent cells, where they promote andCell 126, 503–514, August 11, 2006 ª2006 Elsevier Inc. 511
maintain proliferative arrest. Although HMGA proteins
may contribute to the transactivation of senescence-as-
sociated genes (see below), much of their antiproliferative
activity appears to reflect their ability to produce a higher-
order chromatin environment that serves as a buffer
against the action of mitogenic transcription factors
such as E2F. Thus, HMGA proteins act in a mutually rein-
forcing manner with p16INK4a to promote SAHF formation
and contribute independently to the stable repression of
E2F target genes. Accordingly, suppression of both
HMGA and p16INK4a in growing cells acts synergistically
to enable cells to bypass senescence and leads to the re-
activation of some E2F target genes and S phase re-entry
in senescent cells. Thus, HMGA proteins act as part of the
program that initiates and maintains the senescent state.
HMGA proteins are involved in many cellular processes,
including proliferation, differentiation, and apoptosis
(Reeves, 2001). These HMGA activities are associated
with its ability to facilitate assembly of the ‘‘enhanceo-
some’’ and create a chromatin environment conducive
to transcription. Our study demonstrates that HMGA pro-
teins can function in another process—cellular senes-
cence. In principle, HMGA proteins could contribute to se-
nescence through their enhanceosome activities, perhaps
leading to the upregulation of senescence-associated
genes such as p16INK4a. However, our gene-profiling ex-
periments indicate that their primary action in senescent
cells is to promote gene repression, particularly of prolifer-
ation-associated genes. Although we cannot prove these
effects are direct, the fact that HMGA proteins contribute
to heterochromatin formation suggests that the primary
role of these proteins in senescence is to contribute to a re-
pressive chromatin environment that limits transcription.
Heterochromatin is characterized by the chromatin ac-
cumulation of certain modified histones such as me-
K9H3, which produces a docking site for HP1. These bio-
chemical alterations lead to chromatin compaction and
gene silencing, although how this occurs is not fully under-
stood. Our studies suggest that theHMGAproteins can be
structural components of heterochromatin, at least in the
context of SAHFs. Thus, in senescent cells HMGA pro-
teins localize to condensed regions of DNA that also con-
tain me-K9H3 and HP1.Moreover, enforced expression of
either HMGA protein can trigger the formation of hetero-
chromatic foci, and suppression of HMGA proteins, par-
ticularly HMGA1, can dissolve SAHFs in senescent cells.
Precisely how HMGA proteins contribute to heterochro-
matin formation remains to be determined. However, our
studies strongly suggest that this activity involves its
canonical ability to bind the minor groove of AT-rich
DNA sequences since chemicals that compete with
HMGA for binding the minor groove of DNA can produce
a morphological decondensation of chromatin in senes-
cent cells. Notably, these agents do not displace the het-
erochromatin protein, HP1, implying that HMGA and HP1
act in parallel to produce a highly condensed DNA state.
This cooperative relationship may also underlie themutual
dependence of p16INK4a and HMGA in senescence—with512 Cell 126, 503–514, August 11, 2006 ª2006 Elsevier Inc.p16INK4a acting in part to trigger histone methylation and
recruitment of HP1 through its action on Rb (Nielsen
et al., 2001; Vandel et al., 2001), and HMGA proteins con-
tributing to a higher-order chromatin state. Importantly,
the role of HMGA proteins in heterochromatin structure
may not be limited to cellular senescence, since HMGA
proteins have been noted on the inactive X chromosome
and in pericentric heterochromatin (Chadwick andWillard,
2003; Harrer et al., 2004), which also contains DNA se-
quences that are AT rich (Dillon, 2004).
That HMGA proteins contribute to heterochromatic
structures and gene repression is surprising in light of
work linking HMGA proteins to more open chromatin con-
figurations and transcriptional activation. These opposing
observations suggest that the activity of HMGA proteins
can be modulated, perhaps producing distinct effects on
the local chromatin structure and transcription of target
genes. Interestingly, HMGA proteins can be phosphory-
lated, acetylated, and methylated at specific amino acids
and, perhaps like histones, the type, location, and extent
of such modifications control their ability to promote
open or closed chromatin states (Reeves, 2001; Sgarra
et al., 2004). Indeed, the location of HMGA1 acetylation
can influence transcription from the IFN-b locus (Munshi
et al., 2001), and HMGA controls distinct subsets of genes
in normal and senescent cells. In any case, by linking
HMGA proteins to SAHFs and senescence, our study re-
enforces the importance of global chromatin remodeling
for the senescence program.
The action of HMGA proteins in senescence provides
insights into their role in cancer development. Previous
studies link the HMGA genes to oncogenesis and show
that high levels of HMGA proteins can promote prolifera-
tion, transformation, and tumorigenesis (Reeves et al.,
2001; Takaha et al., 2004). Here we see that HMGA pro-
teins can have antiproliferative activities as well. Thus,
as has been described for TGF-b (Siegel and Massague,
2003), HMGA proteins may be both pro- and antionco-
genic, depending on the cellular context. Consistent with
this view, haploinsufficiency ofHmga1 causes myelo-lym-
phoproliferative disorders in mice (Fedele et al., 2006).
Overcoming the antiproliferative activities of HMGA pro-
teins may be an important step during carcinogenesis.
EXPERIMENTAL PROCEDURES
Vectors and Viral Infections
The following retroviral and lentiviral vectors were used in this study:
pBabe-Puro (Oncogenic ras [H-rasV12]), pBabe-EGFP (H-rasV12),
pWZL-Hygro (H-rasV12, EGFP-tagged human HMGA1 and HMGA2,
INK4a, E1A, p53175H, and CDK4) (Serrano et al., 1997), pWZL-Blastici-
din (H-rasV12), pWZL-Neo (HDM2), pLPC-Puro (E1A, EGFP-tagged
human HMGA1 and HMGA2, and HA-tagged human HMGA2) (Narita
et al., 2003), pSin-Puro (p16INK4a shRNA), pSin-Hygro (p16INK4a
shRNA), pSin-Puro-miR30 (HMGA1 and HMGA2 shRNAs), pSin-
Hygro-miR30 (p53 shRNA), and pRRL.Sin-18 lentiviral vector (INK4a,
HMGA1 andHMGA2 shRNAs,miR30 control, andGSE22) (Beausejour
et al., 2003). Human HMGA1 and HMGA2 were cloned by RT-PCR
from total RNA of IMR90 cells. Information on the RNAi vectors and tar-
get sequences are available in Supplemental Data. Human diploid
IMR90, WI38, and BJ fibroblasts (ATCC) were cultured in DMEM sup-
plemented with 10% FBS and antibiotics. Retroviral and lentiviral gene
transfer was performed as described (Beausejour et al., 2003; Narita
et al., 2003). Lentivirus supernatant was diluted with culture medium
and applied to IMR90 cells 9 days after introduction of ras.
Cell Proliferation, Transformation, and SA-b-Gal Assays
BrdU incorporation was measured as described (Narita et al., 2003).
For population-doubling analysis, cells were counted and 43 105 cells
were plated on 10 cm plates every 3–4 days. For colony formation as-
says, 1 3 103, 3 3 103, or 1 3 104cells were plated on 3.5 cm plates.
Cells were fixed with 4% formaldehyde and stained with Crystal violet
(Sigma). Dye intensity was quantified using ‘‘ImageJ’’ software (http://
rsb.info.nih.gov/ij/). For focus formation assays, 3 3 105 cells were
plated on 3.5 cm plates. Cells were fixed and stained with Giemsa
(Sigma). Cells were assessed for tumorigenicity in immunocompro-
misedmice as described (Seger et al., 2002). SA-b-gal activity was de-
tected as described (Narita et al., 2003). Data are presented asmean ±
standard error. Differences were analyzed by Student’s t test, and
p value < 0.05 was considered to be statistically significant.
Gene Expression
Indirect immunolabeling was performed as described (Narita et al.,
2003). Cells were pre-extracted in the CSK buffer with 0.3 mg/ml dig-
itonin (Sigma) before fixation for HP1g staining. The following primary
antibodies were used: anti-HMGA1 (1:1000, provided by V. Giancotti),
anti-HMGA2 (1:200, provided by V. Giancotti), anti-HP1g (Chemicon,
1:1000), anti-BrdU (Pharmingen, 1:500), anti-GFP (Clontech, 1:50),
anti-me-K9H3 (Upstate, 1:500), and anti-Ac-K9/14H3 (Upstate,
1:1000) antibodies. Alexa Fluor Conjugates (Molecular Probes) were
used as the secondary antibodies, and DNA was visualized by using
4’,6-diamidino-2-phenylindole (DAPI) (1 mg/ml). Confocal images
were obtained using a Zeiss LSM 510 confocal laser-scanning micro-
scope. Electron microscopy was performed as described (Narita et al.,
2003). The primary antibodies against HMGA1 and HMGA2 and the
secondary antibodies conjugated to 10 nm colloidal gold were used.
Western blotting analysis was carried out as described (Narita et al.,
2003). Blots were probed with the following antibodies: anti-HMGA1
(1:4000, provided by V. Giancotti), anti-HMGA2 (1:1000, provided by
V. Giancotti), anti-p16INK4a (H-156, Santa Cruz, 1:1000), anti-p53
(Do-1, Oncogene, 1:1000), anti-HP1b (Chemicon, 1:1000), anti-HP1g
(Chemicon, 1:5000), anti-Ac-K9/14H3 (Upstate, 1:4000), anti-cyclin A
(Sigma, 1:1000), anti-HA (12CA5 hybridoma supernatant, 1:100),
anti-CDK4 (provided by G.J. Hannon, 1:2000), anti-Hdm2 (2A10 and
4B11, 1:250, provided by A. Levine), anti-a-tubulin (B-5-1-2, Sigma,
1:5000), and anti-actin (ac-15, Sigma, 1:5000) antibodies. Quantitative
RT-PCR was performed as described (Narita et al., 2003).
For microarray analysis, total RNA was purified by RNeasy columns
(Qiagen) and utilized for cRNA preparation by Message AmpII (Am-
bion). cRNA was hybridized to U133 Plus 2.0 microarrays (Affymetrix)
according to themanufacturer’s instructions. Two biological replicates
were performed for each experimental condition. Data were analyzed
with GeneTraffic UNO (Stratagene) and the with KEGG pathway data-
base (http://apps1.niaid.nih.gov/david/).
Cell Fractionation, Chromatin Isolation, and Protein Sequencing
Cell fractionation was performed as described with minor modifica-
tions (Mendez and Stillman, 2000). Cells were resuspended in buffer
A (10mMHEPES [pH 7.9], 10mMKCl, 1.5 mMMgCl2, 0.34M sucrose,
10% glycerol, 1 mM DTT, protease inhibitor cocktail [Complete,
Roche], 0.1 mM phenylmethylsulphonyl fluoride). Digitonin (Sigma,
0.3 mg/ml) was added, and the cells were incubated for 10 min
on ice. Nuclei were collected by low-speed centrifugation (4 min,
1300 3 g, 4C) and supernatants were isolated as cytoplasmic fac-
tions. Nuclei were washed once in buffer A and lysed in buffer B
(3 mM EDTA, 0.2 mM EGTA, 1 mM DTT, protease inhibitors as de-
scribed above). After being incubated on ice for 30min with occasionalvortexing, the insoluble chromatin factions were isolated by low-speed
centrifugation and supernatants served as nucleoplasmic fractions.
After vigorous washing with buffer B, the chromatin pellets were resus-
pended in DNase I (Roche) solution (2 3 103 units/ml DNase I, 20 mM
Tris [pH7.5], 10 mM MgCl2) and incubated on ice for 1 hr. Samples
were subjected to SDS-PAGE. The excised gel bands were trypsinised
following standard procedures and analyzed by LC-MS/MS. The re-
sulting spectra were analyzed using the SONARS search engine.
Hoechst Competition Assay
ras-induced senescent IMR90 cells (postselection day 7), plated on
coverslips, were incubated with 10 mg/ml Hoechst 33258 (Molecular
Probes) for 2 days. The cells were fractionated as described above,
followed by immunoblotting, or fixed with 4% formaldehyde, followed
by DNA staining in 0.2% Triton X-100 and DAPI/PBS.
Supplemental Data
Supplemental Data include seven figures experimental procedures,
references, and four tables and can be found with this article online
at http://www.cell.com/cgi/content/full/126/3/503/DC1/.
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Note Added in Proof
Inmarked contrast to our findings in normal diploid fibroblasts, a recent
report indicates that HMGA2 can bind Rb and counteract its ability to
inhibit E2F activity, leading to enhanced E2F target gene activation in
tumor cells. These observations further underscore the context depen-
dency of HMGA2 action in cellular proliferation and transformation,
even at the level of E2F target genes.
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